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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a classic glycolytic enzyme, and accumulating evidence has suggested that
GAPDH is a multi-functional protein. In particular, its role as a mediator for cell death has been highlighted. For the last decade, many
groups reported that a pool of GAPDH translocates to the nucleus under a variety of stressors, most of which are associated with oxidative
stress. At the molecular level, sequential steps lead to nuclear translocation of GAPDH during cell death as follows: first, a catalytic
cysteine in GAPDH (C150 in rat GAPDH) is S-nitrosylated by nitric oxide (NO) that is generated from inducible nitric oxide synthase
(iNOS) and/or neuronal NOS (nNOS); second, the modified GAPDH becomes capable of binding with Siah1, an E3 ubiquitin ligase, and
stabilizes it; third, the GAPDH-Siah protein complex translocates to the nucleus, dependent on Siah1’s nuclear localization signal, and
degrades Siah1’s substrates in the nucleus, which results in cytotoxicity. A recent report suggests that GAPDH may be genetically
associated with late-onset of Alzheimer's disease. (−)-deprenyl, which has originally been used as a monoamine oxidase inhibitor for
Parkinson's disease, binds to GAPDH and displays neuroprotective actions, but its molecular mechanism is still unclear. The NO/GAPDH/
Siah1 death cascade will contribute to the molecular understanding of a role of GAPDH in neurodegenerative disorders and help to
establish novel therapeutic strategies.
© 2006 Elsevier B.V. All rights reserved.Keywords: GAPDH; Nuclear translocation; Oxidative stress; Nitric oxide; Siah1; Apoptosis1. GAPDH: more than a housekeeping glycolytic enzyme
For many decades, glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) has been regarded merely as a housekeeping
glycolytic enzyme that exists mainly in the cytoplasm.
However, a variety of recent studies are now suggesting that
GAPDH is a multifunctional protein [1,2].Abbreviations: AD, Alzheimer's disease; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; iNOS, inducible nitric oxide synthase; MAO-B,
monoamine oxidase B; NLS, nuclear localization signal; NMDA, N-methyl-D-
aspartate; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; SIN-1, 3-
morpholinosydnonimine; SNAP, S-nitroso-N-acetylpenicillamine; SNP, sodium
nitroprusside
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doi:10.1016/j.bbadis.2006.01.012GAPDH binds to microtubules and modulates microtubule
bundling [3–5], and also contributes to membrane fusion [6,7].
Gross and colleagues [8] proposed a scheme whereby an
isoform of GAPDH, recruited by GTP-activated Rab to vesicles
associated with microtubules, is sequentially phosphorylated by
protein kinase C and catalyzes membrane fusion [9,10].
GAPDH also binds to the inositol 1,4,5-trisphosphate receptor
(IP3R), modulating calcium flux [11].
GAPDH exists in the nucleus and plays a role in gene
transcription, DNA replication, DNA repair, and nuclear RNA
export [12–15]. Sirover and colleagues revealed that GAPDH
functions as a uracil DNA glycosylase (UDG), involved in
DNA repair mechanisms [14]. UDGs repair uracils in DNA
caused by cytosine deamination. GAPDH is found in the
nucleus of human cells in a cell-cycle dependent manner [16],
and has been identified as a necessary component for the proper
functioning of an Oct-1 coactivator, OCA-S, that is essential for
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[15]. Consistent with this, GAPDH was isolated as a single-
stranded DNA-biding protein, which is a possible activator of
transcription in neurons [12]. It has also been found that nuclear
GAPDH associates with telomeric DNA and plays a functional
role in maintenance of telomeres [17].
In addition to the various functions of GAPDH described
above, recent studies have clarified a role for this molecule
during cell death, frequently associated with oxidative stress
[2,18–33]. Furthermore, GAPDH binds to several proteins
that are responsible for neurodegenerative diseases, such as
amyloid precursor protein and Huntingtin [34,35], but the
role of GAPDH in these protein interactions is still unclear.
The present mini-review focuses the roles of GAPDH in
pathological conditions, especially cell death triggered by
nitric oxide (NO).
2. GAPDH and Nitric oxide (NO)
NO is one of the major cellular signaling molecules and is
known to mediate cell death. Initially it was shown that NO
causes necrotic cell death via a formation of peroxynitrite, a
powerful oxidant that promotes DNA breaks, lipid peroxidation
and protein oxidation [36]. Further work has revealed that NO
also mediates apoptotic cell death; however, the mechanism is
not well understood [37].
GAPDH had received particular attention as one of the major
targets of NO in cells after the discovery of NO-induced ADP
ribosylation of GAPDH, inhibiting its glycolytic activity
[38,39]. Further work revealed that it was S-nitrosylation
facilitated NAD covalent linkage (not ADP-ribose) [40,41].
Although inhibition of GAPDH glycolytic activity could be a
potential mechanism of NO-induced cell death [42], the field
stalled without a causal link between cell death and NO-
dependent energy depletion [43].
S-nitrosylation has been established by Stamler and
colleagues [44] as a major signaling mechanism for NO. It
occurs at cysteine residues of many proteins in the presence
of NO, and has been shown to affect protein–protein
interactions [45,46]. S-nitrosylation of GAPDH in wild-type
mice, but not in neuronal NO synthase (nNOS) knockout
mice, establishes a physiological relevance for this modifica-
tion [47], however, the significance of S-nitrosylated GAPDH
at basal levels is unknown. Poly(ADP-ribose) polymerase
(PARP) is a downstream mediator of nNOS and NO [48,49].
PARP, once over-activated upon stroke and pathological
conditions with a massive release of glutamate, contributes to
necrotic cell death [48–50]. The glutamate/nNOS/PARP
cascade, however, also plays a role in basal conditions by
regulating neuronal energy dynamics [51]. Similarly, S-
nitrosylated GAPDH may have roles in both basal and
pathological conditions.
3. Nuclear translocation of GAPDH in apoptosis
Chuang and associates [31] initially reported involvement of
GAPDH in apoptosis by using cultured cerebellar granuleneurons. They found a 38-kDa protein that was overexpressed
before age-dependent apoptosis and identified the protein as
GAPDH by N-terminal sequencing. Application of antisense
oligonucleotides to GAPDH in attempts to knock down
expression of GAPDH prevented neuronal cell death, suggest-
ing that a pool of GAPDH might acquire a gain-of-toxic
function during cell death. Similar observations were obtained
from cerebral cortical culture and cerebellar granule cells with a
variety of stress types including cytosine arabinoside (AraC)
and reduced concentrations of KCl [22,32,33].
Following these studies, we discovered a general role for
GAPDH in multiple models of cell death in cell cultures from
diverse tissues, including primary thymocytes, S49 lymphocyte
cells, PC12 cells, and cerebral cortical neurons [23]. In
thymocytes and S49 cells, overexpression of GAPDH occurs
after the addition of dexamethasone (Dex). Antisense oligonu-
cleotides, but not sense, to GAPDH delay the cytotoxicity (Fig.
1A). Besides the overall overexpression of GAPDH, we
discovered a striking translocation of GAPDH to the nucleus
which was much larger than its increased overall expression
(Fig. 1B) [23].
Several other groups have also observed nuclear translo-
cation of GAPDH during cell death [18–21,24,25,27–30].
Furthermore, they highlighted oxidative stresses such as
H2O2 or FeCN [30], or 1-methyl-4-phenylpyridinium
(MPP+) [27,28], as triggers of this nuclear translocation.
Saunders [25] reported that GAPDH purified from the
nucleus of apoptotic cells is resistant to in vitro SNP-
induced NAD labeling, suggesting that GAPDH translocated
to the nucleus may have the catalytic cysteine (C150 in rat
GAPDH) occupied as a result of a posttranslational
modification.
In the nucleus of apoptotic cells, GAPDH is enriched in the
fraction that is resistant to DNase/detergent, biochemically
similar to the nuclear matrix [23]. GAPDH reportedly binds to
PML [52], a main component of the nuclear bodies that are
biochemically enriched in the DNase/detergent resistant nuclear
matrix. PML was originally identified as a fused protein with
the retinoic acid receptor alpha (RAR alpha) in the t(15;17)
translocation specifically associated with acute promyelocytic
leukemia (APL).
In contrast to irreversible translocation of GAPDH to the
nucleus during cell death, reversible nuclear shuttling of
GAPDH has also been reported [15,53]. In the S-phase of
HeLa cells, a pool of GAPDH is particularly enriched in the
soluble fractions of the nucleus and functions as a
transcriptional co-activator [15]. It is not clear whether
DNA repair and replication as described above are carried
out by cell cycle-associated, reversibly translocated GAPDH.
GAPDH contains a nuclear export signal (NES) that
functions in a chromosome region maintenance (CRM)1-
dependent manner [54]. In DLD1 and SW620 cell lines,
treatment with leptomycin B (LMB), an inhibitor of CRM1-
mediated nuclear export, leads to the accumulation of
GAPDH in the nucleus. Additionally, CRM1 was found to
co-immunoprecipitate with a GAPDH, but not with a
GAPDH NES mutant. Another group, however, has reported
Fig. 1. Nuclear translocation of GAPDH in apoptosis (adopted from Sawa et al. [23]). (A) The effect of antisense oligonucleotides to GAPDH was tested in
dexamethasome (Dex)-induced apoptosis in primary thymocytes. After Dex stimulation (3 μM), cytotoxicity was monitored by a trypan blue exclusion assay.
Antisense oligonucleotides to GAPDH protect, with levels increased half of the way to control levels. By contrast, GAPDH sense oligonucleotides have no effects. (B)
Biochemical characterization of nuclear GAPDH in Dex-treated S49 cells. (Upper) Before stimulation, GAPDH is mainly in cytosolic and P3 fractions with less in P2
and no staining in the nuclear fraction (N). After Dex stimulation, a substantial amount of GAPDH translocates to the nucleus (N). (Lower) Nuclear GAPDH resists
extraction; DNase I treatment or high salt treatment (up to 5M NaCl) fails to elute GAPDH from the nuclear pellet fractions.
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independent manner in NIH3T3 cells after serum starvation
[55].
4. Molecular mechanism for nuclear translocation of
GAPDH in apoptosis
Molecular events underlying the nuclear translocation of
GAPDH and related cell death have been elusive, as GAPDH
lacks a nuclear localization signal (NLS). Moreover, GAPDH
forms a 150-kDa homo-tetramer, which is required for its pro-
apoptotic actions in the nucleus, is too large for passive entry
into the nucleus. Therefore, it is postulated that there would be
carrier proteins that bind to GAPDH and would be needed to
facilitate the translocation of GAPDH to the nucleus by active
mechanism(s).
4.1. Binding of GAPDH and Siah1: their bi-directional
functions for cytotoxicity [56]
Our group hypothesized that a protein interactor(s) of
GAPDH may play an active role in translocating GAPDH to
the nucleus. The yeast two-hybrid screening pointed to an
E3 ubiquitin ligase Siah1, because Siah1 is the only clone
that contains a well-conserved NLS in its open reading
frame. Exogenously overexpressed Siah1 can translocate
GAPDH to the nucleus, but Siah1 with site-directed
mutations in the NLS does not, suggesting a role of the
NLS in Siah1 in nuclear translocation of GAPDH. In turn,
GAPDH stabilizes rapidly turning-over Siah1 in the nucleus.
This stabilization of Siah1 protein by GAPDH is due to
their direct protein binding, as a mutation at lysine 225
(K225) in GAPDH that abolishes the GAPDH-Siah1 protein
binding (Fig. 2) results in no more stabilization of Siah1
protein. Downstream of Siah1, degradation of Siah1’ssubstrates in the nucleus may be responsible for cytotoxicity
because deletion of the endogenous NLS sequences and
RING finger domain, essential for protein degradation in
Siah1, abolishes cytotoxicity. Nuclear GAPDH contributes to
cell death mainly by inducing cytotoxic actions of Siah1 as
a result of its protein stabilization.
4.2. S-nitrosylation of GAPDH as a potential trigger for its
binding to Siah1
There are two GAPDH genes in mammalian cells with a
variety of pseudogenes [57]. GAPDH2, localized on chromo-
some 19, is expressed only in spermatogenic cells [58], while
GAPDH, found on chromosome 12, is nearly ubiquitously
expressed. To explore a general role for GAPDH in cell death,
we focused on the more ubiquitous isoform of GAPDH coded
for by the GAPDH gene on chromosome 12.
We considered whether specific molecular alterations of
GAPDH trigger the binding of GAPDH to Siah1. Studies
with mass spectrometry have clarified that C150 is
sulphonated in HEK293 cells during cell death induced by
NO donors, such as SNP (Fig. 2). This observation
substantiates the previous report by Saunders et al. [25]
that GAPDH purified from the nucleus of apoptotic cells is
resistant to in vitro SNP-induced NAD labeling, suggesting
that nuclear GAPDH may be modified at C150. Sulphona-
tion of cysteine can arise after S-nitrosylation (–SNO) via
hydrolysis to sulphenic acid (–SOH) and sequential
oxidation to sulphinic acid (–SO2H), and then sulphonic
acid (–SO3H) (Fig. 3) [44]. Biochemical and cellular
experiments have shown that the protein interaction of
GAPDH and Siah1 is dramatically augmented when
GAPDH is S-nitrosylated. The NO-induced modification at
C150 of GAPDH seems to be a specific trigger that leads to
GAPDH-Siah1 signaling.
Fig. 3. Cascade from S-nitrosylation to sulphonation. Sulphonation of cysteine
can arise after S-nitrosylation (–SNO) via hydrolysis to sulphenic acid (–SOH)
and sequential oxidation to sulphinic acid (–SO2H), and then sulphonic acid
(–SO3H). Sulphonation of cysteine can also be produced with sequential
modifications with reactive oxygen species (ROS).
Fig. 2. Molecular structure of GAPDH. Rat GAPDH has 332 amino acids, and functional domains and key nucleotides have been elucidated. C150 is the catalytic
center of glycolytic activity, where specific modifications (S-nitrosylation, sulphonation) occur by NO. The relative relationship of this cysteine to the adjacent cysteine
is conserved among species as CXXXC. The crucial amino acid for the binding with Siah1 is lysine 225 (K225). Proline 234 (P234) is known to have a role in the
binding of GAPDH to microtubules. GAPDH binds to NAD+/NADH at the Rossmann fold in its N-terminal region. GAPDH binds to polyglutamine-containing
proteins, such as Huntingtin and ataxin-1.
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cultures [56]
The NO/GAPDH/Siah1 cascade seems to have a role in cell
death of a variety of cell cultures, including primary neurons.
Neuronal cell death in the brain following glutamate excitotoxi-
city has been associated with excess production of NO by nNOS,
as neurotoxicity is diminished in pure neuronal cultures by
inhibition of nNOS [59]. In cerebellar granule neurons, cultures
from wild-type, but not from nNOS knockout mice, display
augmented interaction of GAPDH and Siah1 after the exposure
of the glutamate derivative N-methyl-D-aspartate (NMDA),
suggesting that the NO/GAPDH/Siah1 signaling plays a role in
excitotoxic neuronal cell death. This is confirmed by the
observation that knocking down expression of GAPDH and
Siah1 by RNA interference (RNAi) treatment led to decreased
neuronal death. Consistent with protective actions by RNAi
treatment, antisense oligonucleotides to GAPDH were previ-
ously used to prove a causal role of GAPDH in cell death [22,23].
Conceivably, the effects of RNAi and antisense oligonucleotides
imply that newly synthesized GAPDH may have some role in
cellular toxicity. GAPDH-Siah1 binding is decreased with an
addition of NAD+ or glyceraldeyde-3-phosphate (Hara, M.R.,
Sawa, A., and Snyder, S.H.: unpublished observation), indicat-
ing that newly synthesized GAPDH, which may not be bound to
its glycolytic substrates, may bemore susceptible to binding with
Siah1. This issue remains to be clarified.
The NO/GAPDH/Siah1 cascade for neuronal cell death may
be triggered by another mechanism. Activation of microglia can
induce apoptosis in adjacent neurons [60], and the involvement
of inducible NOS (iNOS) in this process has been reported
[61,62]. In a co-culture of microglial and neuronal cells,
stimulation of iNOS in microglia with lipopolysaccharide
leads to increased levels of S-nitrosylated GAPDH in neuronal
cells. Under this condition, the protein interaction of GAPDH
and Siah1 is augmented, which is followed by neuronal cell
death (Hara, M.R., Snyder, S.H., and Sawa, A.: unpublished
observation).The study described above [56] has established that GAPDH
is a mediator of cell death that is triggered by NO (Fig. 4).
PARP is also a mediator of cell death downstream of excess
production of NO. DNA damage by NO leads to overactivation
of PARP and results in depletion of NAD+/ATP as well as
energy depletion. Thus, NO/PARP signaling mediates necrotic
cell death [48–50]. In contrast, NO/GAPDH/Siah1 pathway
utilizes a proteasome-dependent degradation of Siah1’s sub-
strates that requires energy, and which results in apoptotic cell
death [56].
p53 is a key player in sensing cellular stress, and is involved
not only in cancer formations but also in neurodegenerative
conditions [63,64]. Upon recognition of cell stress, p53 binds to
specific DNA sequences to regulate transcription of distinct
genes. Siah1b, one of two mouse homologues of human Siah1,
has been shown to be a direct transcriptional target of p53 and
contains a specific p53 response element within its second intron
[65]. Additionally, p53 has been shown to upregulate GAPDH in
cerebellar granule neurons upon treatment with AraC [21].
Cumulatively, these findings suggest that, in some context, p53
may function upstream of the GAPDH/Siah1 cascade.
Fig. 4. Schematic diagram of NO/GAPDH/Siah1 death signaling (Modified from Hara et al. [56]). NO causes S-nitrosylation of GAPDH at C150. S-nitrosylation of
GAPDH augments its binding to Siah1 at K225. NLS of Siah1 mediates nuclear translocation of GAPDH. GAPDH stabilizes Siah1 facilitating its degradation of
nuclear proteins, which leads to cell death.
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oxidative stress in general, as hydrogen peroxide or peroxyni-
trite treatment of GAPDH elicits the GAPDH-Siah1 binding,
but is less effective than S-nitrosylation [56]. Because reactive
oxygen species and NO may interact in protein S-nitrosylation,
as reported for superoxide [66], they may have a synergistic
effect on the GAPDH-Siah1 cascade.
5. GAPDH in neurodegenerative conditions
A pathological role for GAPDH has been suggested in
several neurological disorders, but its detailed understanding at
the molecular level is still awaited. For example, GAPDH may
be implicated in Alzheimer's disease (AD). Immunoreactivity
of GAPDH was reported in senile plaques in AD [67] and
exposure of cortical neurons to amyloid β peptide causes
nuclear accumulation of disulfide-linked GAPDH [68]. Specific
mutations in amyloid precursor protein (APP) cause familial
forms of AD, and the C-terminal portion of APP binds to
GAPDH [34]. These observations, although very interesting,
have been taken with some reservation, because GAPDH is a
very abundant and sticky molecule. A recent intriguing report
indicated that the strongest association of chromosome 12p with
late-onset AD occurs inside the GAPDH locus [57].
A pathological role forGAPDHhas also been reported in other
neurological conditions. Nuclear accumulation of GAPDH in
apoptotic neurons in the penumbra after middle cerebral artery
occlusion (MCAO) and reperfusion was recently reported [69].
GAPDH immunoreactivity has been observed in Lewy bodies,
the pathological hallmark of Parkinson's disease [70]. In
polyglutamine diseases such as Huntington's disease, GAPDH
binds to the disease gene products (Huntingtin, etc.) in a
polyglutamine tract-dependent manner (Fig. 2) [35,71–73]. The
significance of these protein bindings has yet to be elucidated.
Recent findings have shown, however, that GAPDH immunos-
taining is increased in brain regions such as the neocortex and
caudate putamen/globus pallidus in transgenic mice expressingmutant Huntingtin containing 89 glutamine repeats [74]. GAPDH
staining in these regions indicates a translocation of GAPDH to
the nucleus, and this increased staining is associatedwith cell loss.
It remains controversial whether or not GAPDH glycolytic
activity in brains and fibroblasts of patients with these
neurogenerative diseases is altered [73,75–77]. It will be
important to explore how the NO/GAPDH/Siah1 cascade is
involved in neurodegenerative conditions [56]. The antibody
against the specific GAPDH peptide containing sulphonated
C150 (sGAPDH) may be a useful tool for exploring this
possibility. If the unique staining, especially in the nucleus, is
observed with the sGAPDH antibody in brains from patients
with AD or other conditions, this will suggest that the NO/
GAPDH/Siah1 cascade may be involved in the diseases. Tanaka
et al. [69] presented an antibody which may preferentially detect
nuclear GAPDH in the ischemic core and penumbra region after
focal ischemia. It would be interesting to compare the staining
pattern of this antibody and sGAPDH antibody.
6. GAPDH as a novel therapeutic target
GAPDH is a multifunctional protein important for general
cell maintenance as well as an executor of cell death, thus
therapeutic approaches aimed at simple reduction of GAPDH
levels may not be effective. Instead, a targeted blockade of the
specific pool of GAPDHwith a gain of toxic function may be an
efficient strategy to block GAPDH-mediated cell death in
pathological conditions. In concrete, a strategic block of the
GAPDH/Siah1 interaction may be effective in preventing cell
death in neurological conditions.
The concept of a pool of GAPDH as amediator for apoptosis has
also been suggested pharmacologically [18,19,78–81]. (−)-depre-
nyl, a monoamine oxidase B (MAO-B) inhibitor, is neuroprotective
via mechanisms that do not appear to involve inhibition of MAO-B.
A deprenyl derivative, TCH346 (CGP 3466) (dibenzo[b,f]oxepin-
10-ylmethyl-methyl-prop-2-ynyl-amine), lacks MAO-B inhibitory
activity but is comparably neuroprotective. (−)-deprenyl and
Fig. 5. Scheme of NO/GAPDH/Siah1 death signaling for future therapeutic targets. First, the blockade of GAPDH and Siah1 binding may be an effective way to
prevent cell death from this cascade. Identification of a negative regulator in the cytoplasm (indicated as protein X) that competes with Siah1 for GAPDHmay facilitate
this strategy. Second, identification of Siah1’s substrate(s) in the nucleus will be important. Modulators that block this proteolysis in the nucleus (indicated as protein
Y) may help the strategy. Further exploration of the trigger(s) of the GAPDH/Siah1 cascade is also important.
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GAPDH, which leads to cytoprotective effects [19,81]. In
differentiated PC12 cells, TCH 346 at 0.1 to 1 pico-molar order
blocks nuclear translocation and rescues apoptotic cell death induced
by trophic withdrawal. TCH 346 is cytoprotective in cerebellar
granule neurons with cytosine arabinoside, rat embryonic mesen-
cephalic dopaminergic neurons with MPP+, and PAJU human
neuroblastoma cells with rotenone. Administration of (−)-deprenyl
was neuroprotective in MCAO models in vivo [82].
Based on the molecular understanding of the NO/GAPDH/
Siah1 cascade, we may be able to design new therapeutic
strategies (Fig. 5). First, the blockade of NO-stimulated protein
binding between GAPDH and Siah1 may be an effective way to
prevent cell death from this cascade. Both–deprenyl and
TCH346 have been shown to function in this manner [84].
Identification of a negative regulator in the cytoplasm that may
compete with Siah1 for GAPDH may also facilitate this strategy.
Second, it would be worthwhile exploring the downstream
molecules of the cascade in the nucleus. Bowtell and colleagues
[83] have published a consensus sequence for Siah's substrates. It
will be important to identify nuclear substrate(s) that are degraded
at the endpoint of the NO/GAPDH/Siah1 cascade, which has a
causal role for cytotoxicity. Modulation of these substrates may
be a potential therapeutic strategy against cell death.
7. Concluding remarks
GAPDH is a classic glycolytic enzyme, but recent studies
have highlighted its role as a mediator for cell death. Here we
describe the NO/GAPDH/Siah1 cascade for cell death that is
initiated by a posttranslational modification of GAPDH by NO,
leading to the nuclear translocation of the GAPDH-Siah1
protein complex and cell death. The NO/GAPDH/Siah1 death
cascade would contribute to the molecular understanding of a
role of GAPDH in neurodegenerative disorders and help to
establish novel therapeutic strategies.Acknowledgements
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